Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
Brian J Boyarsky, William A Werbel, Robin K Avery, Aaron A R Tobian, Allan B Massie, Dorry L Segev, Jacqueline M Garonzik-Wang, Brian J Boyarsky, William A Werbel, Robin K Avery, Aaron A R Tobian, Allan B Massie, Dorry L Segev, Jacqueline M Garonzik-Wang
Abstract
This study quantifies antispike protein antibody responses to first-dose messenger RNA (mRNA) COVID-19 vaccines in solid organ transplant recipients to better understand the immunogenicity of the vaccines in immunocompromised individuals.
Conflict of interest statement
Conflict of Interest Disclosures: Dr Avery reported receiving grant support from Aicuris, Astellas, Chimerix, Merck, Oxford Immunotec, Qiagen, and Takeda/Shire. Dr Segev reported serving as a consultant to and receiving honoraria for speaking from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallincrodt, and Thermo Fisher Scientific. No other disclosures were reported.
Source: PubMed